Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.64 |
| ▸ | TNKS | O95271 | 1/20 | 0.58 |
| ▸ | PARP1 | P09874 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.58 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4160586 | 0.86 | TNKS (0.66) | SIGMAR1TNKSPARP1ALOX5TNKS2 | |
| SCHEMBL8782097 | 0.82 | SIGMAR1 (0.61) | SIGMAR1BCHEACHEALDH2MAOA | |
| SCHEMBL8786723 | 0.81 | SIGMAR1 (0.87) | SIGMAR1 | |
| SCHEMBL4160578 | 0.80 | CSNK2A2 (0.81) | TNKSPARP1ALOX5TNKS2POLH | |
| SCHEMBL4152247 | 0.79 | SIGMAR1 (0.65) | SIGMAR1 | |
| SCHEMBL8782608 | 0.77 | SIGMAR1 (0.68) | SIGMAR1BCHEACHEALDH2MAOA | |
| SCHEMBL4160583 | 0.76 | TNKS (0.64) | TNKSPARP1ALOX5TNKS2POLH | |
| SCHEMBL1794203 | 0.76 | XDH (0.67) | SIGMAR1BCHEACHE | |
| SCHEMBL1795639 | 0.75 | SIGMAR1 (0.55) | SIGMAR1BCHEACHE | |
| SCHEMBL12757263 | 0.75 | CSNK2A2 (0.74) | TNKSPARP1ALOX5TNKS2POLH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090130051-A1 | Flavonoid Compounds and Uses Thereof | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2009-05-21 | — | — | US | claimed |
| US-20020147353-A1 | Novel flavonoids | VERENIGING CHRISTELIJK WETENSCHAPPELIJK ANDERWIJS (NL) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147353-A1 | Novel flavonoids | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, ABCC8 | SIGMAR1 747/4885TNKS 4638/4885PARP1 2448/4885 |
| US-20090130051-A1 | Flavonoid Compounds and Uses Thereof | CAT, NQO1, GPX4 | SIGMAR1 2276/4885TNKS 3218/4885PARP1 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.